IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B

Hepatology

Volumn 57, Issue 3, 2013, Pages 890-896

  Lampertico, Pietro ^a   Viganò, Mauro ^a   Cheroni, Cristina ^b   Facchetti, Floriana ^a   Invernizzi, Federica ^a   Valveri, Vincenza ^b   Soffredini, Roberta ^a   Abrignani, Sergio ^b   De Francesco, Raffaele ^b   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIGEN; CYTOSINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THYMINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ANTIBODY TITER; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STRATIFIED SAMPLE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENETIC TESTING; GENOTYPE; HEPACIVIRUS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84874471701     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25749     Document Type: Article

References (31)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
5. Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011; 43: 259-265.
6. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. HEPATOLOGY 1989; 10: 198-202.
7. Hadziyannis S, Bramon T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment for HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol 1990; 11(Suppl. l): S133-S136.
8. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313.
9. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270.
10. Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, et al. Long-term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366-1372.
11. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-109.
12. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. HEPATOLOGY 1997; 26: 1621-1625.
13. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
14. Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. HEPATOLOGY 2003; 37: 756-763.
15. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.
16. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine, and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
17. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: state of the art in 2010. HEPATOLOGY 2011; 53: 336-345.
18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 46: 399-401.
19. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
20. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
21. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
22. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.
23. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-2314.
24. Ishak K, Baptista A, Bianchi L, Suchindran S, Lao XQ, Patel K, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
25. Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009; 14: 1183-1188.
26. Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. HEPATOLOGY 2010; 52: 454-461.
27. Rijckborst V, Hansen BE, Ferenci F, Brunetto MR, Tabak F, Cakaloglu Y, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 weeks of peginterferon alfa-2a therapy. HEPATOLOGY 2010; 52(Suppl 4): 479A.
28. Sonneveld MJ, Wong VW, Wotman AM, Wong GLH, Buster EHCJ, Hansen BE, et al. Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg)-interferon in HBeAg-positive chronic hepatitis B. J Hepatol 2011; 54 (Suppl 1): S32.
29. Sarasin-Filipowicz M, Oakeley EJ, Duong F, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. PNAS 2008; 105: 7034-7039.
30. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, et al. IL28B polymorphism predicts virologic response in atients with hepatitis C genotype 1 treated with boceprevir (Boc) combination therapy. J Hepatol 2011; 54(Suppl 1): S6.
31. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J Hepatol 2011; 54(Suppl 1): S542-S543.